NASDAQ · Biotechnology · USD
Psyence Biomedical Ltd. (PBM) Stock Analysis
Psyence Biomedical Ltd. (PBM) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
PBM Key Statistics
As of Oct 21, 2026Trading
- Open
- $4.52
- Previous Close
- $4.24
- Day's Range
- 4.37–4.66
- 52-Week Range
- 1.92–134.38
- Volume
- 36.79K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.69
Valuation
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −12.56
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$6.94M−785.56%
- 1-Year Return
- −96.64%
Dividend and dates
- Avg Volume
- 81.54K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, PBM closed at $4.52, −96.64% over 1 year.
In fiscal 2025, PBM reported revenue of $0.00.
PBM Stock Return by Calendar Year
Psyence Biomedical Ltd. (PBM) return since Dec 2021: what $10,000 became
- 1 year
- $10,000 $336
- −96.64%
- 3 years
- $10,000 $0.17
- −99.998%
- Since Dec 2021
- $10,000 $0.19
- −99.998%
If you had invested $10,000 in Psyence Biomedical Ltd. (PBM) at the close on December 10, 2021, the earliest close on record here, it would have been worth $0.19 at the close on October 21, 2026: −99.998% in total, −89.25% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −84.63% |
| 2025 | −95.54% |
| 2024 | −99.70% |
| 2023 | −10.12% |
| 2022 | +3.73% |
| 2021 (partial year) | +0.10% |
As of October 21, 2026.
PBM Revenue and Earnings by Fiscal Year
FY ends March| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$6.94M | — |
| 2024 | $0.00 | $1.01M | — |
| 2023 | $0.00 | −$51.16M | — |
| 2022 | $0.00 | −$3.21M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$5.95M | −$6.94M | — |
| 2024 | $0.00 | — | −$3.66M | $1.01M | — |
| 2023 | $0.00 | — | −$43.35M | −$51.16M | — |
| 2022 | $0.00 | — | −$3.23M | −$3.21M | — |
Annual figures as reported, in the company's reporting currency. As of March 31, 2026.
Recent News
Psyence BioMed Completes PsyLabs Investment as Ibogaine Milestones Are Met
YahooPsyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine
YahooPsyence Biomedical Signs Manufacturing Services Agreement With DEA-Registered Benuvia For Planned U.S. Manufacture Of Pharmaceutical-Grade Ibogaine Active Pharmaceutical Ingredient
BenzingaPsyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation
YahooPsyence Biomedical Unit TIRC Signs Binding Term Sheet With Psyence Labs For An Exclusive License, Supply And Wholesale Distribution Arrangement For Psylabs’ Pharmaceutical-Grade Ibogaine In The U.S.
BenzingaPsyence BioMed Announces Strategic Ibogaine Investment
Yahoo
All 8 articles ↓Show fewer ↑
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B